StageZero Life Sciences Ltd. (SZLSF)
SZLSF Stock Price Chart
Explore StageZero Life Sciences Ltd. interactive price chart. Choose custom timeframes to analyze SZLSF price movements and trends.
SZLSF Company Profile
Discover essential business fundamentals and corporate details for StageZero Life Sciences Ltd. (SZLSF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
8 Sept 2009
Employees
40.00
CEO
James R. Howard-Tripp
Description
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.
SZLSF Financial Timeline
Browse a chronological timeline of StageZero Life Sciences Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 15 Dec 2025
Earnings released on 3 Sept 2025
Earnings released on 28 Aug 2025
Earnings released on 26 Jun 2025
Earnings released on 16 May 2025
Earnings released on 16 Dec 2024
EPS came in at -$0.00 , while revenue for the quarter reached $499.66K .
Earnings released on 30 Sept 2024
EPS came in at -$0.01 , while revenue for the quarter reached $390.08K .
Earnings released on 15 May 2024
EPS came in at -$0.00 , while revenue for the quarter reached $519.59K .
Earnings released on 28 Mar 2024
Earnings released on 14 Nov 2023
EPS came in at -$0.01 , while revenue for the quarter reached $745.49K .
Earnings released on 14 Aug 2023
EPS came in at -$0.00 , while revenue for the quarter reached $793.31K .
Earnings released on 31 Mar 2023
EPS came in at -$0.09 , while revenue for the quarter reached $778.52K .
Earnings released on 30 Mar 2023
EPS came in at -$0.16 , while revenue for the quarter reached $676.48K .
Earnings released on 14 Nov 2022
EPS came in at $0.01 , while revenue for the quarter reached $799.40K .
Earnings released on 15 Aug 2022
EPS came in at -$0.01 , while revenue for the quarter reached $998.20K .
Earnings released on 16 May 2022
EPS came in at -$0.01 , while revenue for the quarter reached $1.32M .
Earnings released on 31 Mar 2022
EPS came in at -$0.05 , while revenue for the quarter reached $1.50M , missing expectations by -15.67%.
Earnings released on 15 Nov 2021
EPS came in at -$0.02 , while revenue for the quarter reached $684.32K .
Earnings released on 16 Aug 2021
EPS came in at -$0.03 , while revenue for the quarter reached $404.72K .
Earnings released on 17 May 2021
EPS came in at -$0.11 , while revenue for the quarter reached $2.48M .
Earnings released on 1 Apr 2021
EPS came in at $0.01 , while revenue for the quarter reached $2.59M .
Earnings released on 20 Nov 2020
EPS came in at -$0.10 , while revenue for the quarter reached $1.46M .
Stock split effective on 18 Sept 2020
Shares were split 1 : 8 , changing the number of shares outstanding and the price per share accordingly.
SZLSF Stock Performance
Access detailed SZLSF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.